Risk of hepatocellular carcinoma in antiviral treatment-naive chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.

ABSTRACT:

Background

Long-term antiviral treatments are associated with a significantly lower hepatocellular carcinoma (HCC) incidence in chronic hepatitis B (CHB) patients by reducing HBV DNA concentrations. However, it is still controversial whether antiviral strategies affect HCC development in antiviral treatment-naïve CHB patients. This study aimed to estimate the incidence of HCC in antiviral treatment-naïve CHB patients who were treated with Entecavir (ETV) and Tenofovir Disoproxil Fumarate (TDF) and compare the efficacy of two treatment regimens in HCC reduction.

Methods

The PubMed, Embase, China National Knowledge Infrastructure, and Wanfang databases were systematically searched until June 24, 2021. The pooled incidence and 95% confidence interval of HCC were calculated by t

SUBMITTER: Huang ZH 

PROVIDER: S-EPMC8930063 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature